The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cidara Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $17.58 Mil. Cidara Therapeutics's average Accounts Receivable for the
three
months ended in Dec. 2023 was $9.55 Mil.
Hence, Cidara Therapeutics's Receivables Turnover for the
three
months ended in Dec. 2023 was 1.84.
Cidara Therapeutics Receivables Turnover Historical Data
The historical data trend for Cidara Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cidara Therapeutics's Receivables Turnover
For the Biotechnology subindustry, Cidara Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cidara Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cidara Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cidara Therapeutics Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Cidara Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Cidara Therapeutics (Cidara Therapeutics) Business Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDTX has been successfully added to your 